key: cord-0757588-2ro2p77q
authors: Babadaei, Mohammad Mahdi Nejadi; Hasan, Anwarul; Vahdani, Yasaman; Bloukh, Samir Haj; Sharifi, Majid; Kachooei, Ehsan; Haghighat, Setareh; Falahati, Mojtaba
title: Development of remdesivir repositioning as a nucleotide analog against COVID-19 RNA dependent RNA polymerase
date: 2020-05-20
journal: J Biomol Struct Dyn
DOI: 10.1080/07391102.2020.1767210
sha: 41eaa91ed988209f44b12d82accde002481f4924
doc_id: 757588
cord_uid: 2ro2p77q

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative representative of a severe respiratory illness resulted in widespread human infections and deaths in nearly all of the countries since late 2019. There is no therapeutic FDA-approved drug against SARS-CoV-2 infection, although a combination of anti-viral drugs is directly being practiced in some countries. A broad-spectrum of antiviral agents are being currently evaluated in clinical trials, and in this review, we specifically focus on the application of Remdesivir (RVD) as a potential anti-viral compound against Middle East respiratory syndrome (MERS) -CoV, SARS-CoV and SARS-CoV-2. First, we overview the general information about SARS-CoV-2, followed by application of RDV as a nucleotide analogue which can potentially inhibits RNA-dependent RNA polymerase of COVs. Afterwards, we discussed the kinetics of SARS- or MERS-CoV proliferation in animal models which is significantly different compared to that in humans. Finally, some ongoing challenges and future perspective on the application of RDV either alone or in combination with other anti-viral agents against CoVs infection were surveyed to determine the efficiency of RDV in preclinical trials. As a result, this paper provides crucial evidence of the potency of RDV to prevent SARS-CoV-2 infections. Communicated by Ramaswamy H. Sarma

The new coronavirus (CoV), known as Severe Acute Respiratory Syndrome (SARS)-CoV-2, which is currently spreading around the world, can lead to a respiratory illness that can be exacerbated Novel, 2020; . The disease known as CoV diseases-19 (COVID-19) appears to induce a mortality rate of less than 2%, which is lesser that of most epidemics that have ever become global headlines Pan et al., 2020) . CoVs are very similar to influenza viruses and show almost identical symptoms (Heymann & Shindo, 2020; Rothan & Byrareddy, 2020) . Two recent outbreaks of the new CoV, including severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) have originated from animals (Gretebeck & Subbarao, 2015; Song et al., 2019; Yao et al., 2014) . The diseases caused by these viruses were extremely fatal to humans, and very few cases were reported as mild or asymptomatic. However, it has been reported that the mortality rate of COVID-19 has been more than that of SARS and MERS (Mahase, 2020; Peeri et al., 2020) .

In the past days, it has been repeatedly reported that a vaccine for the SARS-CoV-2 has been discovered, but vaccines, like other medicines, require a lengthy testing process to be approved for medical applications (Ahmed et al., 2020; Prompetchara et al., 2020) . One strategy to date is the replication of a piece of virus RNA that could one day serve as a vaccine (Enayatkhani et al., 2020) . Although, well-developed DNA sequencing devises has let to rapid genetic sequencing, vaccine development is costly, complex, and time intensive (Plotkin et al., 2017) . This includes finding a viral sequence that, while providing memory to the immune system, does not lead to an acute inflammatory reaction. Achieving this goal requires laboratory experimentation on animal models before subjecting humans. In addition, once the vaccine is discovered, it is not possible to dispatch the sample quickly and easily worldwide. Therefore, pharmaceutical companies have generally found it more profitable to invest in drugs that are used for chronic medical conditions. The CoV, as in case of influenza, may undertake mutations and therefore would require continuous vaccine development.

With Having a considerable number of people worldwide infected with COVID-19, scientists have identified a number of cases of broad-spectrum antiviral agents (BSAAs) that could serve as potential candidates for the treatment of the viral diseases (Andersen et al., 2020; Ianevski et al., 2018) . Indeed, re-purposing of current approved anti-viral drugs could be a solution to treat new viral infections (Guo, 2020; Kouznetsova et al., 2014; Mercorelli et al., 2018; Xu et al., 2016) .

Drug re-purposing means that by examining existing drugs, they will find therapeutic effects on new diseases (Aggarwal et al., 2020; Khan, Jha, et al., 2020; Senathilake et al., 2020) . BSAAs are small molecules that can inhibit different infections by blocking the viral replication (Pant et al., 2020; Xiong et al., 2020; . These drugs block the virus or host-related factors and thus prevent the virus from proliferating, then lowering the level of the virus in the body to an extent that the immune system can inhibit their infection (Cui et al., 2020; Ji & Li, 2020) . BSAA has received special attention with the emergence of numerous new viral diseases. Re-purposing existing drugs, or even rejected drugs, for viral diseases increases the possibility of market success as well as reducing the costs and time required to launch it. The benefit of drug re-purposing is that drug details, such as the stages of chemical synthesis, mass production processes, various stages of clinical trials and many more have been identified beforehand (Aanouz et al., 2020; Gupta et al., 2020) .

There is currently no drug or vaccine to prevent the SARS-CoV-2 infection, but the use of widespread antivirals can be effective against the prophylaxis of this virus (Boopathi et al., 2020; Elmezayen et al., 2020) . For example, chloroquine and remdesivir (RDV, GS-5734) are two drugs that in vitro studies have suggested that they can inhibit the viral replication . Teicoplanin, oritavancin, dalbavancin, and monensin antibiotics also prevent viral replication (Andersen et al., 2020) . Currently, the BSAAs are treatment or pyrophylaxis candidates against SARS-CoV-2 (Senanayake, 2020) .

Furthermore, a combination of BSAAs can be applied against a wider range of viruses, such as those that are not yet well recognized or drug-resistant viruses . Potential clinical trials are currently being conducted on these drugs and their results will be published soon (Li & De Clercq, 2020; Senanayake, 2020) . Perhaps in a near future, BSAAs will be used to treat COVID-19 patients. Although a number of BS have been reported to date, in this review we focused on the RDV as a potential compound that has been assessed on the animal models and reaches the clinical phase against MERS -CoV, SARS-CoV and SARS-CoV-2.

CoVs are a large family of viruses ranging from the common cold virus to the cause of SARS (Cascella et al., 2020; Paules et al., 2020) . The structure of CoV has a common RNA genome and is classified as enveloped viruses (Mackie, 2003) . SARS-CoV-2 originating in China and the city of Wuhan is believed to be a member of the Corona family, which has infected many people to date . Despite the emergence of the virus in China, it is spreading rapidly to other parts of the world Zhu et al., 2020) . Similar cases have been reported in other countries such as Thailand, South Korea, Japan, Taiwan, Australia, and the United States, and even more recently in Iran (Velavan & Meyer, 2020; Zhu et al., 2020) . The disease can be spread through close contact with the infected person, handling contaminated equipment and airborne outbreaks (Velavan & Meyer, 2020) . Most people with hypertension, diabetes, respiratory problems, and weak immune systems are at the higher risk to infection and the likely death from it (Fang et al., 2020) .

CoVs have four types of proteins, including spike (S), envelope (E), membrane (M), and nucleocapsid (N) (Hasan et al., 2020) . S protein is attached to the virus membrane and play an important role in binding and entry into the host cell; hence, targeting this protein with various drugs and inhibitors is one potential approach to combat these types of viruses (Chatterjee, 2020; Lai & Cavanagh, 1997; Woo et al., 2010) . SARS-CoV-2 has proteins on its surface that mediate viral infection by binding to angiotensin-converting enzyme 2 (ACE2) receptor (Batlle et al., 2020; Chen & Hao, 2020) . Therefore, one promising way to stop infection by SARS-CoV-2 is to find a compound that blocks the receptor, and consequently prevent the infection by preventing the interaction of S protein with ACE2 receptor (Andersen et al., 2020; Joshi et al., 2020) . The CoV also has 16 unstructured protein (Nsp 1-16) encoded by ORF1a/1b which act as important co-factors for activation of viral replication enzymes (Figure 1) .

Although a recent research in China suggests bat as the potential source of the virus, there are ongoing researches to clarify the exact origin of the virus (Guo et al., 2020) ( Figure  1 ). Researches into the origin of SARS outbreaks have led to the discovery of many bat viruses. SARS-CoV-2 belongs to this category of SARS-related viruses (Fung et al., 2020) . The two genome sequences of Rhinolophus sinicus show 80% similarity with SARS-CoV-2. The third genome of the Rhinolophus affinis virus, RaTG13, resembles 96% similarity with SARS-CoV-2 (Andersen et al., 2020) . To have better sense of this variation, it is similar to the rate of mutation observed over ten years in the human H3N2 influenza virus strain .

RDV (GS-5734) as a nucleotide analogue was originally developed to treat Ebola (Tchesnokov et al., 2019) . The laboratory assessments has shown that RDV is effective against SARS-CoV (Ju et al., 2020) and MERS-CoV (Gordon et al., 2020) viruses, therefore it can be used as a potential anti-viral agent against SARS-CoV-2 . The mechanism of RDV's anti-viral function is based on the blockage of viral RNA transcription as revealed in molecular examinations using different recombinant viral polymerases Sarma et al., 2020; Tchesnokov et al., 2019; Warren et al., 2016) . Siegel et al. (2017) reported that GS-5734 can be used as a potential candidate for the treatment of Ebola and emerging CoV. Agostini et al. (2018) reported that CoV is susceptible to the RDV targeting the viral polymerase and the nsp14 exoribonuclease (ExoN). They compared the sensitivity of WT and ExoN (-) virus to RDV, which ExoN (-) virus showed a greater decrease in viral titer in the presence of GS-5734 relative to WT virus and the determined EC 50 value for ExoN (-) virus was around 0.019 M, whereas the EC 50 value for to the WT was determined to be 0.087 M (Figure 2A(i) ). This increased inhibition of ExoN (-) virus by GS-5734 (Figure 2A (ii)) indicated that GS-5734 is integrated into viral genome and can be excluded by ExoN (Agostini et al., 2018) . Also, it was shown that the type of CoV, concentration of antiviral drug, type of anti-viral drug, and incubation time can play an important role on the inhibition of virus infection ( Figure 2B Figure 4) . Furthermore, they found that RDV was the only therapeutic agent which remarkably decreased pulmonary infection.

Furthermore, Gordon et al. (2020) and de Wit et al. (2020) revealed that RDV derives anti-viral effects against MERS-CoV though inhibition of RNA polymerase. As with SARS-CoV investigations treated by RDV, similar outcomes were observed for MERS-CoV along with limited weight loss, increased pulmonary activity and decreased virus replication (Sheahan et al., 2017) .

The kinetics of SARS-or MERS-CoV proliferation in animal models is significantly different compared to that in humans. In animal, SARS-CoV or MERS-CoV proliferation in the lung tissue reaches to the maximum at 2 dpi and mortality is stimulated at 7-10 dpi (Douglas et al., 2018; Sheahan et al., 2017) . Thus, the therapeutic window to control infected animal model prior to the peak of CoV proliferation is less than 2 days. In human, MERS-CoV replication in the lung tissue reaches the maximum at 7-10 days after the onset of infections and the disease severity increases to death within 21 days Oh et al., 2016) . Thus, the time for therapeutic handling is substantially divergent in humans and experimentally infected animal models. Although, applying RDV led to a reduction in MERS-CoV pathogenesis and pronounced decrease in viral dose, therapeutic handling did not thoroughly reduce infection. Furthermore, at high levels of CoV, RDV is unable to sustain viral viability and pulmonary cells functionality, despite of remarkable decrease in viral loads. These outcomes are the same as those reported for SARS-CoV, where therapeutic platforms were launched after the peak of virus titer and lung injury did not show any progress in resultant outcomes (Sheahan et al., 2017) . Since SARS-and MERS-CoV infections are controlled by both CoVs and host immune system modulators, therefore early handling of antiviral therapeutics either solely or in combination with other therapeutic drugs, and based on the stage of the disorder progression, can inhibit virus proliferation and immunopathology, switch on repairing systems, or control the pulmonary homeostasis.

Arising viral disorders have resulted in meaningful catastrophic pandemics. Genetic exploration in animal models have shown a pronounced mutation of viral genome in the case of CoV, and have even pointed out some viruses indistinguishable to ongoing and past pathogenic strains in animals (Ge et al., 2013; Woo et al., 2006) . Therefore, in the absence of FDA-approved therapeutics for reducing the human CoV infection, useful broad-spectrum therapeutic platforms against well-known epidemic and zoonotic strains probably pave a way for diminishing the current epidemic diseases.

In the case of CoV, patients were received off-label antiviral drugs as well as immunomodulators, either solely or combined, to reduce severe disease symptoms (Zumla et al., 2016) . However, due to the lack of patient, therapeutic consistency, and verified standard efficiency measurement is a complicated process. Although interferon does not result in improved clinical consequence in MERS-CoV patients (Morra et al., 2018) showed that RDV stimulated superior anti-viral function against MERS-CoV both in vitro and in vivo in comparison with lopinavir/ritonavir-interferon b.

Nucleoside/nucleotide analogues inhibit virus replication by blocking the activity of the polymerase enzyme in the virus (Chhikara et al., 2020; Men endez-Arias et al., 2014) . The usage of nucleoside/nucleotide analogues is a major step in the treatment of patients infected with CoVs due to the appropriate antiviral response (Chhikara et al., 2020) . However, the application of these drugs may lead to genetic variation and subsequent mutation emergence. Hence, the safety of RDV and its broad-spectrum anti-viral activity should be considered before suggesting them as potential alternative candidates for clinical development.

Over the recent years, animal model progression of RDV seems to orient primarily on CoV respiratory infections (Sheahan et al., 2020) . Clinical trials in selective patient populations with CoV or CoV-like diseases are needed to examine the efficacy of the developed drugs. Regarding safety data for RDV, some necessary studies in COVID-19 patients should be conducted to proceed the clinical trials. Studies over CoVlike diseases will probably require the enrollment of a large number of infected patients.

There is currently no approved antiviral drug against SARS-CoV-2 to treat hospitalized patients. Moreover, clinical trials over COVID-19 patients seems to be complicated due to several factors such as inability to apply a placebo, underlying diseases, and evaluating anti-viral drug efficiency. If the synergistic activity of RDV and other anti-viral agents in cell cultures is approved by the current Phase 3 clinical trials in patients with SARS-CoV-2, the outcome may propose a way for developing and performing clinical trials of the relative integration to RDV monotherapy and other anti-viral drug monotherapy for treating patients hospitalized with COVID-19.

Ongoing and future perspectives are trying to determine the resistance of different CoVs to RDV both in vitro and in vivo, and to elucidate whether the mutational strains behave in a same way as wild types.

Due to the emergence of a new respiratory infections such as the SARS-CoV-2, progression of animal studies and subsequent preclinical and clinical trials are required to explore the activity of RDV. Some preclinical explorations are ongoing to examine the potential of the RDV against the SARS-CoV-2. Given application history of RDV in treating a wide range of infections, as well as the outcomes from clinical trials in patients with SARS-and MERS-CoV, reinforces the rationale for additional trials of RDV against a wider range of infectious including COVID-19. The ongoing studies in SARS-CoV-2 supported by the WHO is expected to furnish potential data corresponding to RDV application in treating COVID-19.

Other similar investigations may be envisioned with respect to the increasing identifications of the importance of CoVs as a driving force of COVID-19. Apart from the potential progression of RDV for treating SARS-and MERS-CoVs, the emergence of other viral illnesses may pave the way for clinical trials of RDV derivatives.

The authors declare no conflict of interest. (Sheahan et al., 2020) .

Moroccan medicinal plants as inhibitors of COVID-19: Computational investigations

Repurposing papaverine as an antiviral agent against influenza viruses and paramyxoviruses

Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease

Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies

Discovery and development of safe-in-man broad-spectrum antiviral agents

Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-b1b (MIRACLE trial): Study protocol for a randomized controlled trial

Soluble angiotensin-converting enzyme 2: A potential approach for coronavirus infection therapy

Novel 2019 Coronavirus structure, mechanism of action, antiviral drug promises and rule out against its treatment

Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase

Features, evaluation and treatment coronavirus (COVID-19)

Understanding the nature of variations in structural sequences coding for coronavirus spike, envelope, membrane and nucleocapsid proteins of SARS-CoV-2

The role of angiotensin converting enzyme 2 in coronaviruses/influenza viruses and cardiovascular disease

The SARS-CoV-2 vaccine pipeline: An overview

Corona virus SARS-CoV-2 disease COVID-19: Infection, prevention and clinical advances of the prospective chemical drug therapeutics

Identification of cellular microRNA miR-188-3p with broad-spectrum anti-influenza A virus activity

Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection

An interactive web-based dashboard to track COVID-19 in real time

Adaptive evolution influences the infectious dose of MERS-CoV necessary to achieve severe respiratory disease

Drug repurposing for coronavirus (COVID-19): In silico screening of known drugs against coronavirus 3CL hydrolase and protease enzymes

Reverse vaccinology approach to design a novel multi-epitope vaccine candidate against COVID-19: An in silico study

Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?

A tug-ofwar between severe acute respiratory syndrome coronavirus 2 and host antiviral defence: Lessons from other pathogenic viruses

Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor

The antiviral compound remdesivir potently inhibits RNAdependent RNA polymerase from Middle East respiratory syndrome coronavirus

Animal models for SARS and MERS coronaviruses. Current Opinion in Virology

Old weapon for new enemy: Drug repurposing for treatment of newly emerging viral diseases

The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak-an update on the status

In-silico approaches to detect inhibitors of the human severe acute respiratory syndrome coronavirus envelope protein ion channel

A review on the cleavage priming of the spike protein on coronavirus by angiotensin-converting enzyme-2 and furin

COVID-19: What is next for public health? The Lancet

Novel activities of safe-in-human broad-spectrum antiviral agents

Medicinal chemistry strategies toward host targeting antiviral agents

Initiation, extension, and termination of RNA synthesis by a paramyxovirus polymerase

Discovery of potential multi-target-directed ligands by targeting host-specific SARS-CoV-2 structurally conserved main protease$

Nucleotide analogues as inhibitors of SARS-CoV polymerase

Targeting SARS-Cov-2: A systematic drug repurposing approach to identify promising inhibitors against 3C-like Proteinase and 2'-O-RiboseMethyltransferase

Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2 via integrated computational approach

Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and corona virus disease-2019 (COVID-19): the epidemic and the challenges

The molecular biology of coronaviruses

Therapeutic options for the 2019 novel coronavirus (2019-nCoV)

The reproductive number of COVID-19 is higher compared to SARS coronavirus

Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge

The classification of viruses infecting the respiratory tract

Nucleoside/nucleotide analog inhibitors of hepatitis B virus polymerase: Mechanism of action and resistance

Drug repurposing for viral infectious diseases: How far are we?

Clinical outcomes of current medical approaches for Middle East respiratory syndrome: A systematic review and meta-analysis

Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 Protease against COVID-19

The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China

Viral load kinetics of MERS coronavirus infection

Time course of lung changes on chest CT during recovery from 2019 novel coronavirus (COVID-19) pneumonia. Radiology

Peptide-like and small-molecule inhibitors against Covid-19

Coronavirus infections-more than just the common cold

The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: What lessons have we learned?

The complexity and cost of vaccine manufacturing -An overview

Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic

The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak

In-silico homology assisted identification of inhibitor of RNA binding against 2019-nCoV N-protein (N terminal domain)

Drug repurposing strategies for COVID-19

Virtual screening of inhibitors against spike glycoprotein of 2019 novel corona virus: A drug repurposing approach. Preprints, 1-15

Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses

Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV

Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo [2, 1-f][triazin-4-amino] adenine C-nucleoside (GS-5734) for the treatment of Ebola and emerging viruses

From SARS to MERS, thrusting coronaviruses into the spotlight

Mechanism of inhibition of Ebola virus RNA-dependent RNA polymerase by remdesivir

The COVID-19 epidemic

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures

Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys

Coronavirus genomics and bioinformatics analysis. Viruses

Molecular diversity of coronaviruses in bats

Novel and potent inhibitors targeting DHODH, a rate-limiting enzyme in de novo pyrimidine biosynthesis, are broad-spectrum antiviral against RNA viruses including newly emerged coronavirus SARS-CoV-2

Broad spectrum antiviral agent niclosamide and its therapeutic potential

Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

An animal model of MERS produced by infection of rhesus macaques with MERS coronavirus

Epidemic trend of corona virus disease 2019 (COVID-19) in mainland China. Zhonghua yu Fang yi Xue za Zhi

Coronaviruses -drug discovery and therapeutic options